KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Account Payables (2016 - 2019)

NovoCure's Change in Account Payables history spans 6 years, with the latest figure at $126000.0 for Q2 2019.

  • For Q2 2019, Change in Account Payables fell 87.6% year-over-year to $126000.0; the TTM value through Jun 2019 reached $9.6 million, up 32.46%, while the annual FY2018 figure was $9.5 million, 926.35% up from the prior year.
  • Change in Account Payables for Q2 2019 was $126000.0 at NovoCure, down from $3.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.7 million in Q4 2018 and bottomed at -$6.8 million in Q3 2016.
  • The 5-year median for Change in Account Payables is $1.7 million (2015), against an average of $1.1 million.
  • The largest YoY upside for Change in Account Payables was 371.28% in 2016 against a maximum downside of 547.42% in 2016.
  • A 5-year view of Change in Account Payables shows it stood at $2.4 million in 2015, then soared by 78.6% to $4.2 million in 2016, then decreased by 27.48% to $3.1 million in 2017, then surged by 117.34% to $6.7 million in 2018, then tumbled by 98.11% to $126000.0 in 2019.
  • Per Business Quant, the three most recent readings for NVCR's Change in Account Payables are $126000.0 (Q2 2019), $3.2 million (Q1 2019), and $6.7 million (Q4 2018).